Uncoupling of collagen II metabolism in newly diagnosed, untreated rheumatoid arthritis is linked to inflammation and antibodies against cyclic citrullinated peptides

Journal of Rheumatology

Volumn 37, Issue 6, 2010, Pages 1113-1120

  Christensen, Anne Friesgaard ^a   Hørslev Petersen, Kim ^h   Christgau, Stephan ⁱ   Lindegaard, Hanne Merete ^a   Lottenburger, Tine ^h   Junker, Kirsten ^b   Hetland, Merete Lund ^c   Stengaard Pedersen, Kristian ^g   Jacobsen, Søren ^d   Ellingsen, Torkell ^g   Andersen, Lis Smedegaard ^h   Hansen, Ib ^g   Skjødt, Henrik ^c   Pedersen, Jens Kristian ^h   Lauridsen, Ulrik Birk ^c   Svendsen, Anders Jørgen ^a   Tarp, Ulrik ^g   Pødenphant, Jan ^c   Heegaard, Niels H H ^e   Vestergaard, Aage ^f   Jurik, Anne Grethe ^g   Østergaard, Mikkel ^c   Junker, Peter ^a   more..

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^d Rigshospitalet   (Denmark)

^e STATENS SERUM INSTITUT   (Denmark)

^f Mental Health Services CPH   (Denmark)

^g AARHUS UNIVERSITY HOSPITAL   (Denmark)

^h Rheumatism Hospital   (Denmark)

ⁱ Novo A/S   (Denmark)

Author keywords

Autoantibodies; Cartilage; Collagen; Rheumatoid arthritis; Synovitis

Indexed keywords

BETAMETHASONE; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 2; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; CYCLOSPORIN; METHOTREXATE;

ADULT; AGED; AMINO TERMINAL SEQUENCE; ARTICLE; COLLAGEN DEGRADATION; COLLAGEN METABOLISM; COLLAGEN SYNTHESIS; CONTROLLED STUDY; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INFLAMMATION; JOINT RADIOGRAPHY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SYNOVITIS;

ADOLESCENT; ADULT; AGED; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; BIOLOGICAL MARKERS; CARTILAGE, ARTICULAR; COLLAGEN TYPE II; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PEPTIDES, CYCLIC; PROCOLLAGEN; SEVERITY OF ILLNESS INDEX; SYNOVITIS; YOUNG ADULT;

EID: 77953208549     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.091265     Document Type: Article

References (46)

1. Sherrer YS, Bloch DA, Mitchell DM, Young DY, Fries JF. The development of disability in rheumatoid arthritis. Arthritis Rheum 1986;29:494-500.
2. Emery P, McInnes IB, van Vollenhoven R, Kraan MC. Clinical identification and treatment of a rapidly progressing disease state in patients with rheumatoid arthritis. Rheumatology 2008;47:392-398
3. Morel J, Combe B. How to predict prognosis in early rheumatoid arthritis. Best Pract Res Clin Rheumatol 2005;19:137-146
4. Ollier WER, Harrison B, Symmons D. What is the natural history of rheumatoid arthritis? Best Pract Res Clin Rheumatol 2001;15:27-48.
5. Garnero P, Rousseau JC, Delmas PD. Molecular basis and clinical use of biochemical markers of bone, cartilage, and synovium in joint disease. Arthritis Rheum 2000;43:953-968
6. Christgau S, Garnero P, Fledelius C, Moniz C, Ensig M, Gineyts E, et al. Collagen type II C-telopeptide fragments as an index of cartilage degradation. Bone 2001;29:209-215
7. Garnero P, Gineyts E, Christgau S, Finck B, Delmas PD. Association of baseline levels of urinary glucosyl-galactosyl-pyrodinoline and type II collagen C-telopeptide with progression of joint destruction in patients with early rheumatoid arthritis. Arthritis Rheum 2002;46:21-30.
8. Young-Min S, Cawston TE, Marshall N, Coady D, Christgau S, Saxne T, et al. Biomarkers predict radiographic progression in early rheumatoid arthritis and perform well compared with traditional markers. Arthritis Rheum 2007;56:3236-3247
9. Garnero P, Landewe R, Boers M, Verhoeven A, Van Der Linden S, Christgau S, et al. Association of baseline levels of markers of bone and cartilage degradation with long-term progression of joint damage in patients with early rheumatoid arthritis: the COBRA study. Arthritis Rheum 2002;46:2847-2856
10. Peltonen L, Halila R, Ryhänen L. Enzymes converting procollagens to collagens. J Cell Biochem 1985;28:15-21.
11. Ryan MC, Sandell LJ. Differential expression of a cysteine-rich domain in the amino-terminal propeptide of type II (cartilage) procollagen by alternative splicing of mRNA. J Biol Chem 1990;265:10334-10339 (Pubitemid 20212757)
12. Lui V, Ng J, Nicholls J, Tam P, Cheah K. Tissue-specific and differential expression of alternatively spliced alpha1(II) collagen mRNAs in early human embryos. Dev Dyn 1995;203:198-211.
13. Oganesian A, Zhu Y, Sandell LJ. Type IIA procollagen amino propeptide is localized in human embryonic tissues. J Histochem Cytochem 1997;45:1469-1480 (Pubitemid 27465468)
14. Sandell LJ, Morris N, Robbins JR, Goldring MB. Alternatively spliced type II procollagen mRNAs define distinct populations of cells during vertebral development: differential expression of the amino-propeptide. J Cell Biol 1991;114:1307-1319 (Pubitemid 21909888)
15. Zhu Y, McAlinden A, Sandell LJ. Type IIA procollagen in development of the human intervertebral disc: Regulated expression of the NH2-propeptide by enzymic processing reveals a unique developmental pathway. Dev Dyn 2001;220:350-362
16. Zhu Y, Oganesian A, Keene DR, Sandell LJ. Type IIA Procollagen containing the cysteine-rich amino propeptide is deposited in the extracellular matrix of prechondrogenic tissue and binds to TGF-beta 1 and BMP-2. J Cell Biol 1999;144:1069-1080
17. Aigner T, Zhu Y, Chansky HH, Matsen FA, Maloney WJ, Sandell LJ. Reexpression of type IIA procollagen by adult articular chondrocytes in osteoarthritic cartilage. Arthritis Rheum 1999;42:1443-1450
18. Garnero P, Ayral X, Rousseau JC, Christgau S, Sandell LJ, Dougados M, et al. Uncoupling of type II collagen synthesis and degradation predicts progression of joint damage in patients with knee osteoarthritis. Arthritis Rheum 2002;46:2613-2624
19. Christensen AF, Lottenburger T, Lindegaard H, Christgau S, Hørslev-Petersen K, Junker P. Differential association of the N-propeptide of collagen IIA (PIIANP) and the collagen II C-telopeptide (CTX-II) with synovitis and erosions in early and longstanding rheumatoid arthritis. Clin Exp Rheumatol 2009;27:307-314
20. Rousseau JC, Zhu Y, Miossec P, Vignon E, Sandell LJ, Garnero P, et al. Serum levels of type IIA procollagen amino terminal propeptide (PIIANP) are decreased in patients with knee osteoarthritis and rheumatoid arthritis. Osteoarthritis Cartilage 2004;12:440-447
21. Kuhn KA, Kulik L, Tomooka B, Braschler KJ, Arend WP, Robinson WH, et al. Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis. J Clin Invest 2006;116:961-973
22. Hetland ML, Stengaard-Pedersen K, Junker P, Lottenburger T, Ellingsen T, Andersen LS, et al. Combination treatment with methotrexate, cyclosporine, and intraarticular betamethasone compared with methotrexate and intraarticular betamethasone in early active rheumatoid arthritis: an investigator-initiated, multicenter, randomized, double-blind, parallel-group, placebo-controlled study. Arthritis Rheum 2006;54:1401-1409
23. Hetland ML, Stengaard-Pedersen K, Junker P, Lottenburger T, Hansen I, Andersen LS, et al. Aggressive combination therapy with intraarticular glucocorticoid injections and conventional disease-modifying anti-rheumatic drugs in early rheumatoid arthritis: second-year clinical and radiographic results from the CIMESTRA Study. Ann Rheum Dis 2008;67:815-822
24. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-324
25. Thorsen H, Hansen TM, McKenna SP, Sørensen SF, Whalley D. Adaption into Danish of the Stanford Health Assessment Questionnaire (HAQ) and the Rheumatoid Arthritis Quality of Life Scale (RaQol). Scand J Rheumatol 2001;30:103-109
26. Prevoo MLL, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LBA, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Arthritis Rheum 1995;38:44-48
27. van der Heijde D. How to read radiographs according to Sharp/van der Heijde method. J Rheumatol 2000;27:261-263
28. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-1593
29. Sharif M, Kirwan J, Charni N, Sandell LJ, Whittles C, Garnero P. A 5-yr longitudinal study of type IIA collagen synthesis and total type II collagen degradation in patients with knee osteoarthritis - association with disease progression. Rheumatology 2007;46:938-943
30. Mouritzen U, Christgau S, Lehmann HJ, Tanko LB, Christiansen C. Cartilage turnover assessed with a newly developed assay measuring collagen type II degradation products: influence of age, sex, menopause, hormone replacement therapy, and body mass index. Ann Rheum Dis 2003;62:332-336
31. Høier-Madsen M, Nielsen LP, Møller S. Determination of IgM rheumatoid factors by enzyme-linked immunosorbent assay (ELISA). Ugeskr Laeger 1986;148:2018-2021
32. Vasiliauskiene L, Wiik A, Hoier-Madsen M. Prevalence and clinical significance of antikeratin antibodies and other serological markers in Lithuanian patients with rheumatoid arthritis. Ann Rheum Dis 2001;60:459-466
33. Nishimura K, Sugiyama D, Kogata Y, Tsuji G, Nakazawa T, Kawano S, et al. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 2007;146:797-808.
34. Kimura A, Sasazuki T. Eleventh International Histocompatibility workshop reference protocol for the HLA DNA typing technique. In: Tsuji K, Aizawa M, Sasazuki M, editors. HLA 1991. Oxford: Oxford University Press; 1992.
35. Hetland M, Ejbjerg B, Horslev-Petersen K, Jacobsen S, Vestergaard A, Jurik AG, et al. MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2-year randomised controlled trial (CIMESTRA). Ann Rheum Dis 2009;68:384-390
36. Eastell R, Robins SP, Colwell T, Assiri AMA, Riggs BL, Russell RG. Evaluation of bone turnover in type I osteoporosis using biochemical markers specific for both bone formation and bone resorption. Osteoporos Int 1993;3:255-260 (Pubitemid 23252444)
37. Lundberg K, Nijenhuis S, Vossenaar ER, Palmblad K, van Venrooij WJ, Klareskog L, et al. Citrullinated proteins have increased immunogenicity and arthritogenicity and their presence in arthritic joints correlates with disease severity. Arthritis Res Ther 2005;7:R458-67.
38. Trouw LA, Haisma EM, Levarht EW, van der Woude D, Ioan-Facsinay A, Daha MR, et al. Anti-cyclic citrullinated peptide antibodies from rheumatoid arthritis patients activate complement via both the classical and alternative pathways. Arthritis Rheum 2009;60:1923-1931
39. Korganow AS, Ji H, Mangialaio S, Duchatelle V, Pelanda R, Martin T, et al. From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins. Immunity 1999;10:451-461
40. Kouskoff V, Korganow AS, Duchatelle V, Degott C, Benoist C, Mathis D. Organ-specific disease provoked by systemic autoimmunity. Cell 1996;87:811-822
41. Hutamekalin P, Saito T, Yamaki K, Mizutani N, Brand DD, Waritani T, et al. Collagen antibody-induced arthritis in mice: Development of a new arthritogenic 5-clone cocktail of monoclonal anti-type II collagen antibodies. J Immunol Methods 2009;343:49-55.
42. Kirwan JR. The synovium in rheumatoid arthritis: evidence for (at least) two pathologies. Arthritis Rheum 2004;50:1-4.
43. Molenaar ETH, Voskuyl AE, Dinant HJ, Bezemer PD, Boers M, Dijkmans BAC. Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission. Arthritis Rheum 2004;50:36-42.
44. Goldring SR. Pathogenesis of bone and cartilage destruction in rheumatoid arthritis. Rheumatology 2003;42 Suppl 2:ii11-6.
45. Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess 2006;10:iii-iv, xi-xiii, 1-229.
46. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793-2806